Literature DB >> 21193434

Hepatocyte growth factor mobilizes non-bone marrow-derived circulating mesoangioblasts.

Masayoshi Iwasaki1, Masamichi Koyanagi, Hans Kossmann, Nadejda Monsefi, Stefan Rupp, Janina Trauth, Patrick Paulus, Rebekka Goetz, Stefan Momma, Marc Tjwa, Kisho Ohtani, Reinhard Henschler, Dietmar Schranz, Giulio Cossu, Kai Zacharowski, Sven Martens, Andreas M Zeiher, Stefanie Dimmeler.   

Abstract

AIMS: The identification of factors that mobilize subsets of endogenous progenitor cells may provide new therapeutic tools to enhance the repair of ischaemic tissue. We previously identified circulating mesenchymal cells that co-express endothelial markers (so-called circulating mesoangioblasts, cMABs) in children undergoing heart surgery with cardiopulmonary bypass (CPB). However, the mechanisms by which these cells are mobilized and their origin is unclear. METHODS AND
RESULTS: Circulating CD73(+)CD45(-)KDR(+) cMABs were analysed in adults undergoing heart surgery with (n = 21) or without CPB (n = 8). During surgery with CPB, cMABs are mobilized with a maximal response at the end of the operation. In contrast, off-pump heart surgery does not stimulate cMAB mobilization, indicating that the stress mediated by CPB induces the mobilization of cMAB. Circulating mesoangioblasts were enriched in blood obtained from the coronary sinus. Histologically, CD73(+) cells were detected around vessels in the heart, indicating that the heart is one of the niches of cMABs. Consistently, studies in gender mismatched bone marrow transplanted patients demonstrated that cMABs did not originate from the bone marrow. Cytokine profiling of serum samples revealed that hepatocyte growth factor (HGF) was profoundly increased at the time point of maximal mobilization of cMABs. Hepatocyte growth factor stimulated the migration of cMABs. Importantly, injection of recombinant HGF increased cMABs in rats.
CONCLUSIONS: Hepatocyte growth factor induces mobilization of non-haematopoietic progenitor cells with a cardiac repair capacity. This newly identified function together with the known pleiotrophic effects of HGF makes HGF an attractive therapeutic option for the treatment of ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193434     DOI: 10.1093/eurheartj/ehq442

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  Adult cardiac-resident MSC-like stem cells with a proepicardial origin.

Authors:  James J H Chong; Vashe Chandrakanthan; Munira Xaymardan; Naisana S Asli; Joan Li; Ishtiaq Ahmed; Corey Heffernan; Mary K Menon; Christopher J Scarlett; Amirsalar Rashidianfar; Christine Biben; Hans Zoellner; Emily K Colvin; John E Pimanda; Andrew V Biankin; Bin Zhou; William T Pu; Owen W J Prall; Richard P Harvey
Journal:  Cell Stem Cell       Date:  2011-12-02       Impact factor: 24.633

2.  Application of Chinese herbal medicines to revitalize adult stem cells for tissue regeneration.

Authors:  Hing-Lok Wong; Wing-sum Siu; Wai-ting Shum; Si Gao; Ping-Chung Leung; Chun-Hay Ko
Journal:  Chin J Integr Med       Date:  2012-12-13       Impact factor: 1.978

3.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.

Authors:  Bàrbara Flix; Xavier Suárez-Calvet; Jordi Díaz-Manera; Eva Santos-Nogueira; Renzo Mancuso; Jordi Barquinero; Miquel Navas; Xavier Navarro; Isabel Illa; Eduard Gallardo
Journal:  Stem Cells Dev       Date:  2013-07-26       Impact factor: 3.272

4.  MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation.

Authors:  Thomas J Kean; Paul Lin; Arnold I Caplan; James E Dennis
Journal:  Stem Cells Int       Date:  2013-08-13       Impact factor: 5.443

5.  Matrix metalloproteinase 9 secreted by hypoxia cardiac fibroblasts triggers cardiac stem cell migration in vitro.

Authors:  Qing Gao; Maojuan Guo; Wenyun Zeng; Yijing Wang; Lin Yang; Xiaoli Pang; Huhu Li; Yanrong Suo; Xijuan Jiang; Chunquan Yu
Journal:  Stem Cells Int       Date:  2015-02-12       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.